Serum hepcidin and iron status parameters in pregnant women and the association with adverse maternal and fetal outcomes: a study protocol for a prospective cohort study

Gabriela Amstad Bencaiova, Deborah Ruth Vogt, Irene Hoesli, Gabriela Amstad Bencaiova, Deborah Ruth Vogt, Irene Hoesli

Abstract

Introduction: Hepcidin production is normally upregulated by iron stores, and in obesity has been shown to be overexpressed and correlated with low iron status. The increased hepcidin may restrain the iron release from the cells by affecting the expression of ferroportin, which probably associates with the development of diabetes complication. First, we investigate the difference of serum hepcidin and iron parameters between obese and non-obese pregnant women; second, we examine the correlation between serum hepcidin and adverse maternal and neonatal outcomes in pregnant women.

Methods and analysis: This is a mono-centre, prospective cohort study with a study (obese) and a control group (non-obese women). In the first trimester, 188 singleton pregnancies will be recruited. Thereof, we expect 75 with a body mass index (BMI) ≥30 kg/m2 and 113 with a BMI 18.5-30 kg/m2. Serum hepcidin, iron and haematological parameters will be measured at 11-14, 24-28, 32-36 weeks of gestation and at time of delivery. Blood pressure, weight, BMI and smoking status will be examined at all visits. We will assess the composite endpoints adverse maternal outcomes (including pre-eclampsia, gestational hypertension, gestational diabetes mellitus, haemorrhage, placenta abruption) and adverse neonatal outcomes (preterm birth, intrauterine growth restriction, preterm premature rupture of membranes, Apgar score <7 at 5 min, stillbirth, neonatal death).Recruitment has started in April 2019.

Ethics and dissemination: This study received ethical approval from the ethics committee in Basel. The results of the study will be published in a peer-reviewed journal, and presented at national scientific conferences.

Trial registration number: NCT03792464.

Keywords: BMI; hepcidin; pregnancy; pregnancy outcome.

Conflict of interest statement

Competing interests: None declared.

© Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

References

    1. Catalano PM, Shankar K. Obesity and pregnancy: mechanisms of short term and long term adverse consequences for mother and child. BMJ 2017;356 Review 10.1136/bmj.j1
    1. Flynn A, Begum S, White S, et al. . Relationships between maternal obesity and maternal and neonatal iron status. Nutrients 2018;10:E1000 10.3390/nu10081000
    1. van Santen S, Kroot JJC, Zijderveld G, et al. . The iron regulatory hormone hepcidin is decreased in pregnancy: a prospective longitudinal study. Clin Chem Lab Med 2013;51:1395–401. 10.1515/cclm-2012-0576
    1. Hedengran KK, Nelson D, Andersen MR, et al. . Hepcidin levels are low during pregnancy and increase around delivery in women without iron deficiency—a prospective cohort study. J Matern Fetal Neonatal Med 2016;29:1506–8. 10.3109/14767058.2015.1052396
    1. Kulik-Rechberger B, Kościesza A, Szponar E, et al. . Hepcidin and iron status in pregnant women and full-term newborns in first days of life. Ginekol Pol 2016;87:288–92. 10.17772/gp/62202
    1. Simavli S, Derbent AU, Uysal S, et al. . Hepcidin, iron status, and inflammation variables among healthy pregnant women in the Turkish population. J Matern Fetal Neonatal Med 2014;27:75–9. 10.3109/14767058.2013.804054
    1. Garcia-Valdes L, Campoy C, Hayes H, et al. . The impact of maternal obesity on iron status, placental transferrin receptor expression and hepcidin expression in human pregnancy. Int J Obes 2015;39:571–8. 10.1038/ijo.2015.3
    1. Nazif HK, Abd El-Shaheed A, El-Shamy KAI, et al. . Study of serum hepcidin as a potential mediator of the disrupted iron metabolism in obese adolescents. Int J Health Sci 2015;9:167–74. 10.12816/0024114
    1. Dao MC, Sen S, Iyer C, et al. . Obesity during pregnancy and fetal iron status: is hepcidin the link? J Perinatol 2013;33:177–81. 10.1038/jp.2012.81
    1. Bekri S, Gual P, Anty R, et al. . Increased adipose tissue expression of hepcidin in severe obesity is independent from diabetes and NASH. Gastroenterology 2006;131:788–96. 10.1053/j.gastro.2006.07.007
    1. Schulze KJ, Christian P, Ruczinski I, et al. . Hepcidin and iron status among pregnant women in Bangladesh. Asia Pac J Clin Nutr 2008;17:451–6.
    1. Finkenstedt A, Widschwendter A, Brasse-Lagnel CG, et al. . Hepcidin is correlated to soluble hemojuvelin but not to increased GDF15 during pregnancy. Blood Cells, Molecules, and Diseases 2012;48:233–7. 10.1016/j.bcmd.2012.02.001
    1. Chelchowska M, Swiatek E, Ambroszkiewicz J, et al. . [Concentrations of pro-hepcidin in serum of pregnant women and in umbilical cord blood]. Ginekol Pol 2008;79:754–7.
    1. Chen Y, Yin H-qing, Liu H-ling, et al. . Hepcidin and iron metabolism in non-diabetic obese and type 2 diabetic rats. J Huazhong Univ Sci Technolog Med Sci 2015;35:851–7. 10.1007/s11596-015-1517-z
    1. Pihan-Le Bars F, Bonnet F, Loréal O, et al. . Indicators of iron status are correlated with adiponectin expression in adipose tissue of patients with morbid obesity. Diabetes Metab 2016;42:105–11. 10.1016/j.diabet.2015.10.007
    1. Cepeda-Lopez AC, Melse-Boonstra A, Zimmermann MB, et al. . In overweight and obese women, dietary iron absorption is reduced and the enhancement of iron absorption by ascorbic acid is one-half that in normal-weight women. Am J Clin Nutr 2015;102:1389–97. 10.3945/ajcn.114.099218
    1. Yanoff LB, Menzie CM, Denkinger B, et al. . Inflammation and iron deficiency in the hypoferremia of obesity. Int J Obes 2007;31:1412–9. 10.1038/sj.ijo.0803625
    1. The American College of Obstetricians and Gynecologists Hypertension in pregnancy. Task force on hypertension in pregnancy, 2013.
    1. World Health Organization Iron deficiency anaemia. Assessment, prevention, and control. A guide for programme managers, 2001.
    1. World Health Organization Neonatal and perinatal mortality country, regional and global estimates. Country, regional and global estimates, 2006.
    1. UNICEF Levels and trends in child mortality. Report, 2014.
    1. Anelli GM, Cardellicchio M, Novielli C, et al. . Mitochondrial content and hepcidin are increased in obese pregnant mothers. J Matern Fetal Neonatal Med 2018;31:2388–95. 10.1080/14767058.2017.1344209
    1. Cepeda-López AC, Aeberli I, Zimmermann MB, et al. . Does obesity increase risk for iron deficiency? A review of the literature and the potential mechanisms. Int J Vitam Nutr Res 2010;80:263–70. 10.1024/0300-9831/a000033
    1. Rehu M, Punnonen K, Ostland V, et al. . Maternal serum hepcidin is low at term and independent of cord blood iron status. Eur J Haematol 2010;85:345–52. 10.1111/j.1600-0609.2010.01479.x
    1. Cao C, Pressman EK, Cooper EM, et al. . Prepregnancy body mass index and gestational weight gain have no negative impact on maternal or neonatal iron status. Reprod Sci 2016;23:613–22. 10.1177/1933719115607976
    1. Jones AD, Zhao G, Jiang Y-p, et al. . Maternal obesity during pregnancy is negatively associated with maternal and neonatal iron status. Eur J Clin Nutr 2016;70:918–24. 10.1038/ejcn.2015.229
    1. Rawal S, Hinkle SN, Bao W, et al. . A longitudinal study of iron status during pregnancy and the risk of gestational diabetes: findings from a prospective, multiracial cohort. Diabetologia 2017;60:249–57. 10.1007/s00125-016-4149-3
    1. Bowers KA, Olsen SF, Bao W, et al. . Plasma concentrations of ferritin in early pregnancy are associated with risk of gestational diabetes mellitus in women in the Danish national birth cohort. J Nutr 2016;146:1756–61. 10.3945/jn.115.227793
    1. Cardaropoli S, Todros T, Nuzzo AM, et al. . Maternal serum levels and placental expression of hepcidin in preeclampsia. Pregnancy Hypertens 2018;11:47–53. 10.1016/j.preghy.2017.12.008

Source: PubMed

Sponsorzy i współpracownicy

Warunki medyczne

Interwencje lekowe

3
Subskrybuj